Oral Ketamine Safety Review: Clinical and Regulatory Insights

Introduction to Oral Ketamine's Expanding Use

Oral ketamine has emerged as a potential treatment for various conditions beyond its traditional anesthetic role. This systematic review, published on May 30, 2026, in an unknown Tier 1 venue, focuses on the safety and tolerability of oral ketamine, particularly in treatment-resistant depression and pediatric sedation. The review synthesizes data from randomized controlled trials to inform clinical practice and regulatory frameworks.

Mechanism and Context of Ketamine Use

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been studied for its rapid-acting antidepressant effects and its use in procedural sedation. Despite its growing off-label use, particularly in oral form, there is no standardized pharmaceutical formulation. This lack of standardization, coupled with the uncertainty surrounding long-term safety, necessitates a thorough evaluation of its safety profile.

Findings from the Systematic Review

The systematic review included 18 trials, covering a diverse range of participants, including adults, children, and healthy volunteers. The primary outcomes assessed were safety and tolerability. In studies focused on depression (n = 5; 427 participants), adverse effects were generally mild and transient. Pediatric trials (n = 239) reported transient neurological effects without significant safety concerns. Trials involving pain and experimental conditions (n = 372) noted mild adverse events, with dissociative symptoms occurring at higher doses. Serious adverse events were rare across all studies.

Implications for Clinical Practice and Regulation

The findings suggest a favorable short-term safety profile for oral ketamine, which could influence future guidelines and regulatory decisions. However, the review highlights the low certainty of evidence, emphasizing the need for further research. Clinicians and regulators must exercise caution, especially given the absence of a standardized formulation and the uncertainties surrounding long-term use.

Risks, Unknowns, and Future Directions

While the review provides valuable insights into the short-term safety of oral ketamine, significant gaps remain. The low certainty of evidence and the lack of long-term data pose challenges for clinicians and policymakers. Future research should focus on establishing standardized dosing regimens and assessing long-term safety to better inform clinical and regulatory practices.

Conclusion

Oral ketamine holds promise for treating various conditions, but its use must be guided by robust evidence and cautious regulation. As research progresses, stakeholders must prioritize long-term safety to ensure the responsible integration of ketamine into therapeutic settings.